Portal de Periódicos da CAPES

Artigo Produção Nacional Revisado por pares

BIBTEX RIS

Discrimination of non-melanoma skin cancer and keratosis from normal skin tissue in vivo and ex vivo by Raman spectroscopy

2018; Elsevier BV; Volume: 100; Linguagem: Inglês

10.1016/j.vibspec.2018.11.009

1873-3697

Ana Mara Ferreira Lima, Camila Ribeiro Daniel, Ricardo Scarparo Navarro, Benito Bodanese, Carlos Augusto Pasqualucci, Marcos Tadeu Tavares Pacheco, Renato Amaro Zângaro, Landulfo Silveira,

Molecular Biology Techniques and Applications

This study aimed the diagnosis of non-melanoma skin cancer (basal cell carcinoma - BCC, squamous cell carcinoma - SCC) and actinic keratosis (AK) and normal tissue (NO) by means of Raman spectra collected in vivo and ex vivo as well as determine, through the main Raman features, which biochemical element present in the skin is related to the spectral changes in the lesions compared to normal tissue. A total of 471 Raman spectra in vivo and 227 spectra ex vivo from NO, BCC, SCC and AK tissues were collected using a dispersive Raman spectrometer (830 nm excitation, 30 s exposure time, 200 mW laser power) as well as spectra of basal skin constituents (proteins, lipids, nucleic acids). Student's t-test (p < 0.01) was applied to identify the Raman peaks with significant differences of lesion compared to normal skin and discriminant analysis based on Euclidian and Mahalanobis distances were applied to the intensities of the significant peaks. The results showed better discrimination between lesions and normal tissue through Mahalanobis distance both in vivo and ex vivo, with sensitivity, specificity and overall accuracy of 94.1%, 93.6% and 93.8%, respectively, for the in vivo spectra, while the discrimination showed sensitivity, specificity and overall accuracy of 100% for ex vivo tissues. The use of the intensities of the significant Raman peaks in the discrimination model showed results compared to other multivariate methods and may allow faster processing time, increasing the possibility of clinical use.